STERIS (NYSE:STE) Sets New 12-Month Low – What’s Next?

Posted by Logan Wallace on May 5th, 2026

STERIS plc (NYSE:STE – Get Free Report)’s stock price reached a new 52-week low during trading on Tuesday . The stock traded as low as $209.61 and last traded at $212.99, with a volume of 69494 shares. The stock had previously closed at $212.25.

Wall Street Analyst Weigh In

STE has been the subject of several recent analyst reports. Wall Street Zen cut shares of STERIS from a “strong-buy” rating to a “buy” rating in a report on Sunday, April 26th. Weiss Ratings cut shares of STERIS from a “buy (b-)” rating to a “hold (c+)” rating in a report on Thursday, April 16th. Five equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $275.20.

Get Our Latest Analysis on STERIS

STERIS Price Performance

The company has a quick ratio of 1.75, a current ratio of 2.48 and a debt-to-equity ratio of 0.26. The firm has a market capitalization of $20.90 billion, a PE ratio of 29.71 and a beta of 0.95. The firm’s fifty day simple moving average is $226.36 and its 200-day simple moving average is $244.80.

STERIS (NYSE:STE – Get Free Report) last issued its earnings results on Wednesday, February 4th. The medical equipment provider reported $2.53 earnings per share (EPS) for the quarter, hitting the consensus estimate of $2.53. STERIS had a net margin of 12.15% and a return on equity of 14.34%. STERIS’s quarterly revenue was up 9.2% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.32 earnings per share. STERIS has set its FY 2026 guidance at 10.150-10.300 EPS. On average, research analysts forecast that STERIS plc will post 10.22 earnings per share for the current fiscal year.

Insider Buying and Selling at STERIS

In other news, Director Cynthia L. Feldmann sold 3,098 shares of the business’s stock in a transaction that occurred on Thursday, March 5th. The shares were sold at an average price of $237.21, for a total transaction of $734,876.58. Following the completion of the transaction, the director directly owned 705 shares of the company’s stock, valued at $167,233.05. The trade was a 81.46% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 1.07% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Steigerwald Gordon & Koch Inc. purchased a new position in shares of STERIS in the 3rd quarter worth $25,000. Board of the Pension Protection Fund purchased a new position in shares of STERIS in the 4th quarter worth $25,000. Harbor Investment Advisory LLC boosted its stake in shares of STERIS by 115.4% in the 4th quarter. Harbor Investment Advisory LLC now owns 112 shares of the medical equipment provider’s stock worth $28,000 after buying an additional 60 shares during the last quarter. Activest Wealth Management lifted its holdings in STERIS by 423.8% in the fourth quarter. Activest Wealth Management now owns 110 shares of the medical equipment provider’s stock valued at $28,000 after acquiring an additional 89 shares during the period. Finally, Measured Wealth Private Client Group LLC purchased a new position in STERIS in the fourth quarter worth about $28,000. 94.69% of the stock is owned by hedge funds and other institutional investors.

STERIS Company Profile

(Get Free Report)

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.